Trials / Completed
CompletedNCT04047446
Liposomal Bupivacaine vs Dexamethasone ISB
Prolonging the Interscalene Brachial Plexus Block by Adding Liposomal Bupivacaine or Preservative Free Dexamethasone to Bupivacaine: a Non-inferiority Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Hospital for Special Surgery, New York · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In this study, patients receiving shoulder arthroscopy will receive an interscalene block for pain management containing either liposomal bupivacaine and standard bupivacaine or standard bupivacaine and dexamethasone. Patients will be followed up with to determine postoperative pain and block duration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exparel 133 MG Per 10 ML Injection | 10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total) |
| DRUG | Dexamethasone | 15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected |
Timeline
- Start date
- 2019-07-11
- Primary completion
- 2021-03-15
- Completion
- 2021-03-19
- First posted
- 2019-08-06
- Last updated
- 2022-08-01
- Results posted
- 2022-08-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04047446. Inclusion in this directory is not an endorsement.